{
    "nct_id": "NCT04905914",
    "official_title": "A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.\n* Measurable disease defined by RECIST 1.1.\n* Life expectancy â‰¥ 3 months.\n* Subject must be capable of oral administration of study medication.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Patient has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.\n* Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.\n* Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.\n* Known human immunodeficiency virus infection (HIV).\n* Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.\n* Current or past diagnosis of leukemia within the past 5 years.\n* Prior radiotherapy at the target lesion unless there is evidence of disease progression.\n* Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).\n* History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.\n* Patient has uncontrolled hypertension at time of enrollment.\n* Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock).\n* Any clinically significant ST segment and/or T-wave abnormalities.\n* Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.",
    "miscellaneous_criteria": ""
}